• Barbara Lopez Kunz and Myra Davis join the Board of Directors as independent directors 

Since its founding in 1966, Werfen has made numerous strategic moves to establish itself as a leader in specialized diagnostics. With the aim of remaining one of the world leaders in this field, the company has decided to strengthen its Board of Directors by adding new profiles that bring greater knowledge in the sector, digitalization, and new economic and geopolitical scenarios. In the coming years, Werfen will continue to ensure an appropriate balance of family members and independent members with diverse experiences in terms of gender, age, and background. This will enhance the ability to address all current and future challenges more comprehensively.

With the full support of the family and the current Board of Directors, Werfen is adding two new independent female directors: Barbara Lopez Kunz and Myra Davis.

These appointments will take effect in July. With these additions, Werfen strengthens its board in key areas such as talent management, cybersecurity, digitalization, AI, regulatory, Market Access, innovation, and internationalization.Dos nuevas incorporaciones al Consejo de Administración. 

About the new independent directors:

Barbara Lopez Kunz has four decades of experience leading global teams and understands how to drive growth in a dynamic business environment. Her executive experience includes strategic planning, finance, R&D, technology commercialization, people, and culture, all on a global scale.

Known to global regulatory leaders from her time as CEO of the Drug Information Association, Barbara is adept at engaging on policy, strategic, and operational business issues.

In addition, she has more than 15 years of experience as a member of public, private, non-profit, and university boards of directors. She is currently Chair of the Compensation Committee and a member of both the Audit and Nominating & Governance committees of Aptevo Therapeutics. A clinical-stage biotechnology company, Aptevo Therapeutics, focuses on developing immunotherapeutic candidates to treat various types of cancer in the United States. Barbara is also a board member of Caidya, a privately owned clinical research organization focusing on multiple therapeutic areas. 

Myra Davis is the Chief Information Innovation Officer at Texas Children’s Hospital (TCH), a nonprofit healthcare system committed to creating a healthier future for children and women throughout the global community by leading in patient care, education, and research. She is an expert in aligning technology investments with key organizational objectives such as patient care, operational efficiency, and data management. Her colleagues describe her as a thoughtful, collaborative, and results-oriented leader who champions innovation. With her two decades of experience at one of the United States’ leading pediatric hospitals, she will provide us with insights into the US healthcare system.

In addition, Myra has received numerous accolades, including the 2023 Houston ORBIE Award. She was also named one of The Most Powerful Women in Healthcare IT.